|
22 October, 2025
|
ICON Reports Third Quarter 2025 Results
|
|
|
24 September, 2025
|
ICON plc Schedules Third Quarter 2025 Earnings Conference Call
|
|
|
04 September, 2025
|
ICON Announces CEO Transition
|
|
|
02 September, 2025
|
ICON plc to Participate at Upcoming Investor Conferences
|
|
|
23 July, 2025
|
ICON Announces Results of Annual General Meeting
|
|
|
23 July, 2025
|
ICON Reports Second Quarter 2025 Results
|
|
|
16 July, 2025
|
ICON’s Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report
|
|
|
07 July, 2025
|
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
|
|
|
23 June, 2025
|
ICON plc Schedules Second Quarter 2025 Earnings Conference Call
|
|
|
27 May, 2025
|
ICON plc to Present at the William Blair 45th Annual Growth Stock Conference
|
|
|
19 May, 2025
|
ICON releases its ICON Cares 2024 Report
|
|
|
07 May, 2025
|
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies
|
|
|
30 April, 2025
|
ICON Reports First Quarter 2025 Results
|
|
|
31 March, 2025
|
ICON plc Schedules First Quarter 2025 Earnings Conference Call
|
|
|
05 March, 2025
|
ICON plc to Present at Upcoming Investor Conferences
|
|
|
19 February, 2025
|
ICON Reports Fourth Quarter and Full Year 2024 Results
|
|
|
30 January, 2025
|
ICON Portfolio of AI Tools Drives Clinical Trial Efficiencies
|
|
|
29 January, 2025
|
ICON plc Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call
|
|
|
14 January, 2025
|
ICON Issues Financial Guidance for Full Year 2025
|
|
|
08 January, 2025
|
Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey
|
|
